02719nam 2200589 a 450 991082900240332120240516074038.01-283-12126-397866131212640-19-978094-3(CKB)2670000000089197(EBL)716722(OCoLC)729244831(SSID)ssj0000526194(PQKBManifestationID)12175982(PQKBTitleCode)TC0000526194(PQKBWorkID)10519688(PQKB)11670201(MiAaPQ)EBC716722(Au-PeEL)EBL716722(CaPaEBR)ebr10472263(CaONFJC)MIL312126(EXLCZ)99267000000008919720100331d2011 uy 0engur|n|---|||||txtccrtPA for stroke the story of a controversial drug /Justin A. Zivin, John Galbraith Simmons1st ed.New York Oxford University Press20111 online resource (206 p.)Description based upon print version of record.0-19-539392-9 Includes bibliographical references and index.Code stroke on Market street -- Clot-buster : the natural history -- Dead or alive -- Brain-O -- The brain doctors cometh : slowly -- What emergency? -- Money and brains -- Deer in the headlights -- Call 911, 112, 15 ... even 999 -- Persistence of a most controversial drug -- Through the looking glass -- Post-script.Without warning stroke can paralyze, blind, or kill. Some victims recover, but many do not and may even suffer another disabling or fatal attack. The drug known as tPA can drastically reduce the long-term disability associated with stroke, but despite its near-miraculous capabilities and the growing support of most neurologists, it has been slow to win acceptance as the standard of care in emergency departments nationwide. tPA for Stroke chronicles how this remarkable drug came to be tested in stroke victims, its early years in development by the pharmaceutical giant Genentech, and its eventuaCerebrovascular diseaseChemotherapyHistoryTissue plasminogen activatorTherapeutic useHistoryCerebrovascular diseaseChemotherapyHistory.Tissue plasminogen activatorTherapeutic useHistory.616.8/106Zivin Justin A1676179Simmons John1949-1676180MiAaPQMiAaPQMiAaPQBOOK9910829002403321TPA for stroke4042223UNINA